Apollomics Inc. Class A Ordinary Shares (APLM) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Apollomics Inc. Class A Ordinary Shares (APLM) has a cash flow conversion efficiency ratio of -2.622x as of March 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-12.76 Million) by net assets ($4.86 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See net asset quality index of Apollomics Inc. Class A Ordinary Shares to measure how much of total assets are equity-financed.
Apollomics Inc. Class A Ordinary Shares - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how Apollomics Inc. Class A Ordinary Shares's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore long-term investment intensity of Apollomics Inc. Class A Ordinary Shares to see how much of total assets are deployed in long-term investments.
Apollomics Inc. Class A Ordinary Shares Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Apollomics Inc. Class A Ordinary Shares ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Elcomtec Co. Ltd
KQ:037950
|
0.006x |
|
Ihuman Inc
NYSE:IH
|
0.193x |
|
Naga Dhunseri Group Limited
NSE:NDGL
|
0.017x |
|
Daewon Co. Ltd
KQ:007680
|
0.059x |
|
E&E Recycling
TWO:8440
|
0.114x |
|
Monks Investment Trust PLC
LSE:MNKS
|
0.001x |
|
Atico Mining Corporation
V:ATY
|
0.001x |
|
Softing AG
XETRA:SYT
|
0.015x |
Annual Cash Flow Conversion Efficiency for Apollomics Inc. Class A Ordinary Shares (2019–2025)
The table below shows the annual cash flow conversion efficiency of Apollomics Inc. Class A Ordinary Shares from 2019 to 2025. For the full company profile with market capitalisation and key ratios, see Apollomics Inc. Class A Ordinary Shares (APLM) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-3.19 Million | $-10.37 Million | 3.253x | +155.04% |
| 2024-12-31 | $4.86 Million | $-28.74 Million | -5.909x | -463.92% |
| 2023-12-31 | $41.23 Million | $-43.21 Million | -1.048x | -1196.54% |
| 2022-12-31 | $-448.12 Million | $-42.82 Million | 0.096x | -53.03% |
| 2021-12-31 | $-212.86 Million | $-43.31 Million | 0.203x | -27.04% |
| 2020-12-31 | $-127.93 Million | $-35.68 Million | 0.279x | -22.82% |
| 2019-12-31 | $-60.72 Million | $-21.94 Million | 0.361x | -- |
About Apollomics Inc. Class A Ordinary Shares
Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer. The company's products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung… Read more